ArriVent BioPharma Inc — Balance Sheet (NASDAQ:AVBP) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Notizie

ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald

Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock

ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)

Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating

ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug

ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential

ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug

ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street

ArriVent BioPharma’s 32% decline validates InvestingPro’s overvaluation warning

ArriVent reports 16-month PFS for lung cancer drug firmonertinib

H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential